Salud financiera de hoja de balance de BioSyent

Salud financiera controles de criterios 6/6

BioSyent tiene un patrimonio de accionistas total de CA$34.8M y una deuda total de CA$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CA$41.5M y CA$6.8M respectivamente. El BAIT de BioSyent es de CA$7.5M, por lo que su ratio de cobertura de intereses es de -7. Tiene efectivo e inversiones a corto plazo que ascienden a CA$26.2M.

Información clave

Ratio deuda-patrimonio

CA$0

Deuda

Ratio de cobertura de intereses	-7x
Efectivo	CA$26.19m
Patrimonio	CA$34.76m
Total pasivo	CA$6.77m
Activos totales	CA$41.53m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

Mar 22

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Feb 09

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CA$35.9M) de RX superan a sus pasivos a corto plazo (CA$5.5M).

Pasivo a largo plazo: Los activos a corto plazo de RX (CA$35.9M) superan a sus pasivos a largo plazo (CA$1.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: RX está libre de deudas.

Reducción de la deuda: RX no ha tenido ninguna deuda en los últimos 5 años.

Cobertura de la deuda: RX no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: RX no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Salud financiera de hoja de balance de BioSyent

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent Inc., Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024

Upcoming dividend of CA$0.045 per share

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Third quarter dividend increased to CA$0.045

BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024

Upcoming dividend of CA$0.04 per share at 1.9% yield

Price target increased by 13% to CA$9.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023

BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023

BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023

BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Inaugural dividend of CA$0.04 per share

BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CA$10.00

Insufficient new directors

BioSyent Inc. to Report Q3, 2022 Results on Nov 16, 2022

Now 21% undervalued after recent price drop

BioSyent Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. Announces Adoption of Dividend Policy

BioSyent Inc. to Report Q2, 2022 Results on Aug 23, 2022

BioSyent Inc. to Report Q1, 2022 Results on May 18, 2022

Price target increased to CA$10.00

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

BioSyent Inc. to Report Q4, 2021 Results on Mar 09, 2022

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CA$0.14 (vs CA$0.075 in 3Q 2020)

Second quarter 2021 earnings released: EPS CA$0.08 (vs CA$0.056 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CA$0.13 (vs CA$0.11 in 1Q 2020)

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc., Annual General Meeting, May 26, 2021

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2020 earnings released: EPS CA$0.29 (vs CA$0.31 in FY 2019)

Biosyent Inc. Announces Combogesic Availability in Many Pharmacies Across Canada

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent Inc. to Report Q4, 2020 Results on Mar 17, 2021

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$8.19

Investor sentiment improved over the past week

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Revenue and earnings miss expectations

BioSyent Inc. to Report Q3, 2020 Results on Nov 26, 2020

Biosyent Inc. Announces Launch of New Feramax PD Therapeutic 150

Earnings released

New 90-day high - CA$7.10

BioSyent Inc. to Report Q2, 2020 Results on Aug 26, 2020

New 90-day high - CA$6.07

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera